Studies on DEVELOPMENT OF ImMUNOTHERAPY FOR ORAL CANCERS BY INTERLEUKIN 2

口腔癌患者淋巴细胞与白细胞介素2 （IL2）体外培养后，已被证实具有抗肿瘤杀伤活性。研究了外周血淋巴细胞（PBL）、淋巴细胞（LNC）和肿瘤浸润淋巴细胞（TIL）活化杀伤细胞的来源，并用单克隆抗体分析了这些细胞的细胞表面标记物。然后，进行了IL-2免疫治疗口腔癌患者的早期II期临床研究。将PBL与IL-2体外培养5 d，观察其自然杀伤细胞（NK）活性的增强和淋巴因子活化杀伤细胞（LAK）活性的生成。NK和LAK活性的增加无显著性差异。IL-2在健康供者和口腔癌患者及/或肿瘤分期之间的差异。口腔癌患者的LNC经IL-2活化后也表现出较高的NK活性，但LNC的LAK活性明显低于PBL。产生NK和LAK活性的前体淋巴细胞的细胞表面标记物表达CD3 CD16或CD3 Leu7，而在LNC的情况下，不能排除T淋巴细胞表达CD3的可能性。在早期II期临床试验中，已有7例口腔癌患者采用病灶内注射IL-2治疗，9例类似患者采用静脉注射治疗。局部免疫治疗有明显的减瘤效果。同时检测IL-2治疗患者的NK和LAK活性。

The lymphocytes from oral cancer patients have been to be able to generate anti-tumor killer activities by incubating with interleukin 2 (IL2) in vitro. Peripheral blood lymphocytes (PBL), lymphonodal cells (LNC) and tumoe infiltrating lymphocytes (TIL) have been examined for the sourse of the activated killer cells, and cell surface markers of those cells have been analysed by monoclonal antibodies. Then, the early phase II clinical study of immounotherapy with IL-2 on oral cancer patients has been performed.The augumentation of natural killer (NK) activity and the generation of lymphokine activated killer (LAK) activity were observed by in vitro incubation of PBL with IL-2 for 5 days. No significant difference was found in the augumentation of NK and LAK activities. by IL-2 between healthy donors and oral cancer patients and / or tumor stages. LNC from oral cancer patients also showed high NK activity after the activation by IL-2, however, LAK activity of LNC were significantly lower than that of PBL.Cell surface markers of precourser lymphocytes which generate NK and LAK activites expressed either CD3 CD16 or CD3 Leu7, however, possibility of T lymphocytes expreesing CD3 could not be rouled out in case of LNC.As for the early phase II clinical trial, seven oral cancer patients have been treated by intralesional injection of IL-2, and nine similar patients have been treated by intra venous rout. Obvious tumor reduction effect has been observed in some cases of intralesional immunotherapy. NK and LAK activeties of IL-2 treated patients have been also examined.